In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 714 ( 2023-09-20)
Abstract:
Patients with T and B cell lymphomas with gene fusions involving tumor protein p63 gene (TP63) often have poor overall survival. To investigate these fusions, Wu et al . evaluated the mechanism behind the promotion of tumor growth and how to inhibit it. The authors found that these fusions drove tumor survival through EZH2 and, through inhibition of EZH2 with valemetostat, were able to treat patient-derived xenografts harboring TP63 fusions. In addition, one patient with a TP63-rearranged lymphoma responded to valemetostat treatment, suggesting a potential targeted therapy that requires further investigation. —Dorothy Hallberg
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adi7244
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink